UniProt P11362 · PDB · AlphaFold · Substrate: pEY + Mn · Clone: cytoplasmic (aa308-731)
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Pemigatinib | 99.9% | 0.1% | 98.23 | 0.718 |
| 2 | Infigratinib | 99.2% | 0.8% | 98.24 | 0.710 |
| 3 | Futibatinib | 99.0% | 1.0% | 98.48 | 0.718 |
| 4 | Erdafitinib | 99.0% | 1.0% | 95.71 | 0.737 |
| 5 | Ponatinib | 98.9% | 1.1% | 78.23 | 0.534 |
| 6 | Alpelisib | 98.7% | 1.3% | 97.22 | 0.720 |
| 7 | Nintedanib | 95.9% | 4.1% | 90.23 | 0.608 |
| 8 | Axitinib | 94.9% | 5.1% | 93.23 | 0.688 |
| 9 | Brigatinib | 94.7% | 5.3% | 82.96 | 0.513 |
| 10 | Tenalisib | 93.2% | 6.8% | 97.98 | 0.702 |
| 11 | Pralsetinib | 93.2% | 6.8% | 93.43 | 0.643 |
| 12 | Selpercatinib | 87.4% | 12.6% | 96.72 | 0.635 |
| 13 | Pazopanib | 87.3% | 12.7% | 97.49 | 0.672 |
| 14 | Ripretinib | 86.5% | 13.5% | 92.95 | 0.674 |
| 15 | Lenvatinib | 85.5% | 14.5% | 97.74 | 0.726 |
| 16 | Deucravacitinib | 85.1% | 14.9% | 98.99 | 0.718 |
| 17 | Vandetanib | 83.9% | 16.1% | 95.74 | 0.723 |
| 18 | Midostaurin | 77.8% | 22.2% | 78.64 | 0.500 |
| 19 | Entrectinib | 76.8% | 23.2% | 93.69 | 0.671 |
| 20 | Fedratinib | 72.8% | 27.2% | 96.21 | 0.576 |
Paralog block
FGFR1, FGFR2, FGFR3, FGFR4
EMT expression
- Mesenchymal log2(TPM+1): 5.90
- Epithelial log2(TPM+1): 3.17
- Fold change: 2.73
- Status: Upregulated
Selectivity landscape vs inhibition on FGFR1
Each point is one of the 92 approved drugs; color = inhibition % on FGFR1.
Mutation lollipop
Cancer-associated mutations plotted by residue position. Marker size + color scale with the number of distinct cancer reports.
Variants (2)
Mutation × cancer associations
| Mutation | Cancer | Organ | Source |
|---|---|---|---|
| W666R | carcinoma_breast | Breast | ref |
| W666R | carcinoma_lung | Lung | ref |
| V561M | glioma_central_nervous_system | Brain/CNS | ref |
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…